User: vishwas Topic: IP
Category: patent-legal-regime :: everywhere
Last updated: May 24 2017 09:39 IST RSS 2.0
 
1 to 20 of 2,772    
'What we do is determined by national interest' 24.5.2017 Rediff: Business
If people can lobby me for making changes in policies that goes against the country's interest, I won't keep myself in this position, says the vice chairman of NITI Aayog.
Also found in: [+]
Roche vs Indian Pharma: The battle for a cheaper cancer drug 14.5.2017 ET: Pharma
The companies in the thick of it are Roche, a $51 billion Swiss pharma major, and Biocon, the Bengaluru-based company led by India’s first woman pharma-billionaire, Kiran Mazumdar-Shaw.
Also found in: [+]
'India's IPR policy a good first step, needs to address gaps' 13.5.2017 ET: Policy
Both, the companies in the United States and the Trump administration have been expressing concerns over some aspects of the Indian IPR policy.
Also found in: [+]
DIPP, WIPO to set up Technology and Innovation Support Centres for IP generation 8.5.2017 ET: Policy
The Cell for IPR Promotion and Management, under the Ministry of Commerce & Industry, has been designated as the national focal point for the TISC network.
Also found in: [+]
DIPP & WIPO to set up Technology and Innovation Support Centers 8.5.2017 Govt of india: PIB
The Department of Industrial Policy and Promotion (DIPP) and World Intellectual Property Organization (WIPO)have signed an agreement to establish Technology and Innovation Support Centers (TISC)
Also found in: [+]
U.S. to probe Japanese, German automakers over alleged patent violations 1.5.2017 Sify Finance
TOKYO (Reuters) - The United States will begin an investigation into whether thermoplastic components used in some Japanese and German vehicle models sold in the country violate its patent laws,
Also found in: [+]
US keeps India on intellectual property priority watch list 28.4.2017 ET: Policy
On the other hand, India has always maintained that its IPR regime is in compliance with the global rules including that of the World Trade Orgainsation.
Also found in: [+]
US keeps India on intellectual property priority watch list 28.4.2017 TOI: India
The US on Friday retained India on its priority watch list this year for "lack of improvement" in the intellectual property (IP) framework.
Also found in: [+]
Working to cut patent examination time to 18 months: Nirmala Sitharaman 27.4.2017 ET: Policy
The ministry is continuously working on simplification of rules and reducing the patent examination time, Commerce and Industry Minister Nirmala Sitharaman said.
Also found in: [+]
RSS-backed SJM declares 2017 'anti-China year' 14.4.2017 Rediff: Business
'I will be happy if walls are built between India and China!'
Also found in: [+]
IPA punches holes into drug pricing policy implementation 4.4.2017 ET: Pharma
"This is not a good sign. It is indicative of trust deficit in the regulatory mechanism and administrative machinery, be it the NPPA or CDSCO," it added.
Also found in: [+]
`India–EFTA trade talks may adversely impact access to medicines in developing countries' 23.3.2017 TOI: India
Also found in: [+]
Now, even Indian lawyers bank on Artificial Intelligence 21.3.2017 Rediff: Business
With the demand for lower costs in process driven activities and a move away from the high rate, billable hours of legal services, AI platforms are being used internationally in many legal tasks.
Also found in: [+]
Indian drug makers can export patented meds for approval: Delhi High Court 8.3.2017 ET: Pharma
Natco and Alembic, however, were directed to undertake that during the life of the respective patent, they will not export the respective patented invention for purposes other than those specified in section 107A.
Also found in: [+]
Delhi High Court favours Natco, Alembic; allows them to export generics of Bayer's drugs 8.3.2017 ET: Pharma
Bayer had approached court in 2016 to stop Alembic Pharmaceuticals from exporting its generic of the German company's blood thinner brand 'Xarelto' (Rivaroxaban), used to prevent and treat dangerous blood clots.
Also found in: [+]
Pharma lobby cries foul on GIPC’s poor ranking to India 3.3.2017 ET: Pharma
Global Intellectual Property Centre (GIPC) index on intellectual property (IP) standards once again places India at the bottom of 45 countries.
Also found in: [+]
Healthcare and patient groups oppose patents on crucial hepatitis C drugs 15.2.2017 TOI: India
Also found in: [+]
USTR urged not to demand excessive IP enforcement in India 14.2.2017 ET: Infotech
MSF said countries should not be penalised or discouraged from making use of the public health safeguards that are intended to protect access.
Also found in: [+]
US pharma sector demands keeping India in patent violator list 14.2.2017 ET: Pharma
PhRMA in a submission requested US Trade Representative (USTR) to continue to keep India on the Priority Watch List in the 2017 Special 301 Report.
Also found in: [+]
India ranks 43rd out of 45 nations in IP environment: Report 8.2.2017 ET: Indicators
GIPC also highlighted the need for the government to "build upon the positive rhetoric of its IPR policy with the substantial legislative reforms that innovators need".
Also found in: [+]
1 to 20 of 2,772